Floatz logo

Levosimendan

Transient Ischemic Attack

Orion Corporation, Orion PharmaSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
81/ 100

Competitive context

21 Active assets in the Transient Ischemic Attack cohort.

Asset / SponsorPhaseRating
Plavix
Sichuan Provincial People's Hospital
Phase 4BBB
Acetylsalicylic Acid
Sichuan Provincial People's Hospital
Phase 4BBB
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
Stanford University
Phase 4BBB
Ticagrelor
Mazandaran University of Medical Sciences
Phase 3BBB
Apixaban
Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
Phase 4BBB

View all 45 →

Same molecule, other indications

Levosimendan is also rated in:

amyotrophic lateral sclerosisDormant
B
Indicative ·
57 / 100
View asset →
subarachnoid hemorrhageDormant
CCC
Indicative ·
53 / 100
View asset →
stroke disorderDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →